Maria Pippias1, Kitty J Jager1, Anneke Kramer1, Torbjørn Leivestad2, Manuel Benítez Sánchez3, Fergus J Caskey4, Frederic Collart5, Cécile Couchoud6, Friedo W Dekker7, Patrik Finne8, Denis Fouque9, James G Heaf10, Marc H Hemmelder11, Reinhard Kramar12, Johan De Meester13, Marlies Noordzij1, Runolfur Palsson14, Julio Pascual15, Oscar Zurriaga16, Christoph Wanner17, Vianda S Stel1. 1. Department of Medical Informatics, ERA-EDTA Registry, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. 2. Norwegian Renal Registry, Department for Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 3. Department of Nephrology, Hospital Juan Ramon Jimenez, Huelva, Spain. 4. UK Renal Registry, Southmead Hospital, Bristol, UK School of Social and Community Medicine, Canynge Hall, University of Bristol, Bristol, UK. 5. French-Belgian ESRD Registry, Brussels, Belgium. 6. REIN Registry, Agence de la Biomédecine, Saint Denis La Plaine, France. 7. Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands. 8. Department of Nephrology, Helsinki University Central Hospital, Helsinki, Finland Finnish Registry for Kidney Diseases, Helsinki, Finland. 9. Carmen Cens Department of Nephrology, Université de Lyon F-69622, CH Lyon Sud, France. 10. Department of Medicine, Roskilde Hospital, University of Copenhagen, Copenhagen, Denmark. 11. Nefrovisie Renine, Leiden, The Netherlands. 12. Austrian Dialysis and Transplant Registry, Rohr, Austria. 13. Department of Nephrology & Dialysis & Hypertension, Dutch-speaking Belgian Renal Registry (NBVN), Sint-Niklaas, Belgium. 14. Division of Nephrology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland. 15. Department of Nephrology, Hospital del Mar, Barcelona, Spain. 16. Valencia Region Renal Registry, Direccion General de Salud Pública, Conselleria de Sanitat, Valencia, Spain CIBERESP (Biomedical Research Consortium on Epidemiology and Public Health), Madrid, Spain. 17. Renal Division, University Hospital Würzburg, Würzburg, Germany.
Abstract
BACKGROUND: This study examines the time trends in incidence, prevalence, patient and kidney allograft survival and causes of death (COD) in patients receiving renal replacement therapy (RRT) in Europe. METHODS: Eighteen national or regional renal registries providing data to the European Renal Association-European Dialysis and Transplant Association Registry between 1998 and 2011 were included. Incidence and prevalence time trends between 2001 and 2011 were studied with Joinpoint and Poisson regression. Patient and kidney allograft survival and COD between 1998 and 2011 were analysed using Kaplan-Meier and competing risk methods and Cox regression. RESULTS: From 2001 to 2008, the adjusted incidence of RRT rose by 1.1% (95% CI: 0.6, 1.7) annually to 131 per million population (pmp). During 2008-2011, the adjusted incidence fell by 2.2% (95% CI: -4.2, -0.2) annually to 125 pmp. This decline occurred predominantly in patients aged 45-64 years, 65-74 years and in the primary renal diseases diabetes mellitus type 1 and 2, renovascular disease and glomerulonephritis. Between 2001 and 2011, the overall adjusted prevalence increased from 724 to 1032 pmp (+3.3% annually, 95% CI: 2.8, 3.8). The adjusted 5-year patient survival on RRT improved between 1998-2002 and 2003-2007 [adjusted hazard ratio (HRa) 0.85, 95% CI: 0.84, 0.86]. Comparing these time periods, the risk of cardiovascular deaths fell by 25% (HRa 0.75, 95% CI: 0.74, 0.77). However the risk of malignant death rose by 9% (HRa 1.09, 95% CI: 1.03, 1.16) in patients ≥65 years. CONCLUSION: This European study shows a declining RRT incidence, particularly in patients aged 45-64 years, 65-74 years and secondary to diabetic nephropathy. Encouragingly, the adjusted RRT patient survival continues to improve. The risk of cardiovascular death has decreased, though the risk of death from malignancy has increased in the older population.
BACKGROUND: This study examines the time trends in incidence, prevalence, patient and kidney allograft survival and causes of death (COD) in patients receiving renal replacement therapy (RRT) in Europe. METHODS: Eighteen national or regional renal registries providing data to the European Renal Association-European Dialysis and Transplant Association Registry between 1998 and 2011 were included. Incidence and prevalence time trends between 2001 and 2011 were studied with Joinpoint and Poisson regression. Patient and kidney allograft survival and COD between 1998 and 2011 were analysed using Kaplan-Meier and competing risk methods and Cox regression. RESULTS: From 2001 to 2008, the adjusted incidence of RRT rose by 1.1% (95% CI: 0.6, 1.7) annually to 131 per million population (pmp). During 2008-2011, the adjusted incidence fell by 2.2% (95% CI: -4.2, -0.2) annually to 125 pmp. This decline occurred predominantly in patients aged 45-64 years, 65-74 years and in the primary renal diseases diabetes mellitus type 1 and 2, renovascular disease and glomerulonephritis. Between 2001 and 2011, the overall adjusted prevalence increased from 724 to 1032 pmp (+3.3% annually, 95% CI: 2.8, 3.8). The adjusted 5-year patient survival on RRT improved between 1998-2002 and 2003-2007 [adjusted hazard ratio (HRa) 0.85, 95% CI: 0.84, 0.86]. Comparing these time periods, the risk of cardiovascular deaths fell by 25% (HRa 0.75, 95% CI: 0.74, 0.77). However the risk of malignant death rose by 9% (HRa 1.09, 95% CI: 1.03, 1.16) in patients ≥65 years. CONCLUSION: This European study shows a declining RRT incidence, particularly in patients aged 45-64 years, 65-74 years and secondary to diabetic nephropathy. Encouragingly, the adjusted RRT patient survival continues to improve. The risk of cardiovascular death has decreased, though the risk of death from malignancy has increased in the older population.
Authors: Tracey Ying; Bree Shi; Patrick J Kelly; Helen Pilmore; Philip A Clayton; Steven J Chadban Journal: J Am Soc Nephrol Date: 2020-09-09 Impact factor: 10.121
Authors: Samuel Chan; Elaine M Pascoe; Philip A Clayton; Stephen P McDonald; Wai H Lim; Matthew P Sypek; Suetonia C Palmer; Nicole M Isbel; Ross S Francis; Scott B Campbell; Carmel M Hawley; David W Johnson Journal: Clin J Am Soc Nephrol Date: 2019-08-27 Impact factor: 8.237
Authors: Arjan van der Tol; Norbert Lameire; Rachael L Morton; Wim Van Biesen; Raymond Vanholder Journal: Clin J Am Soc Nephrol Date: 2018-12-13 Impact factor: 8.237
Authors: Vikas R Dharnidharka; Abhijit S Naik; David Axelrod; Mark A Schnitzler; Huiling Xiao; Daniel C Brennan; Dorry L Segev; Henry Randall; Jiajing Chen; Bertram Kasiske; Krista L Lentine Journal: Transplantation Date: 2017-04 Impact factor: 4.939